HomeNewsBusinessIndia as manufacturer for the world will take time: Neeraj Jain, former CFO, Johnson & Johnson Medical

India as manufacturer for the world will take time: Neeraj Jain, former CFO, Johnson & Johnson Medical

There have to be very compelling reasons to move manufacturing from China to India. The current global supply demand gap in many industries may not indicate a favourable move to see India as the next destination, says supply chain expert, Neeraj Jain

May 15, 2020 / 23:05 IST
Story continues below Advertisement

Earlier this January, Neeraj Jain doffed his hat as CFO (Vice President, Finance) at Johnson & Johnson Medical. He now spends his time as an angel investor and mentor to young startups and a guest speaker at business schools.

A supply chain expert, Jain spent close to 37 years in various roles across J&J Medical, Lever Johnson and Hindustan Unilever. Here in this first part of a two-part interview, he talks about the impact of COVID-19 on global supply chains.
Edited excerpts from the interview:

Q: What do you make of the promise of land, labour and law reforms in the PM's speech?

Story continues below Advertisement

A: Overall, the provision of Rs 20 lakh crore (though a part was already announced) at 10 percent of GDP is a decent package, but is it enough? The focus has been on MSMEs and migrants without giving away free cash, which the government can ill-afford. Credit lines to MSMEs are being intended as an enabler to sustain through the crisis.

Another area of focus has been easing of labour laws (e.g. in case of Uttar Pradesh) to attract FDI but it will be important to ensure that this relaxation is not abused. While the intent has been good, it is the execution which will hold the key. Also, the industry is still hoping to see further relaxation – for instance, can GST be lowered to spur demand? While the supply side has been the focus, we will need more measures on the demand side.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show